William Blair Remains Bullish on Genmab A/S (GMAB)

Genmab A/S (NASDAQ:GMAB) is one of the top most undervalued biotech stocks to buy now. On August 7, William Blair analyst Matt Phipps reiterated a bullish stance on Genmab A/S (NASDAQ:GMAB), giving the stock a Buy rating without assigning a price target.

Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now?

A scientist in a lab using a microscope to develop new treatments for Multiple Myeloma.

The analyst supported the rating with the company’s solid financial performance and promising pipeline developments, stating that Genmab A/S (NASDAQ:GMAB) surpassed both consensus and internal revenue estimates, reporting strong fiscal Q2 results.

He attributed the growth to a notable sales growth of Epkinly and robust royalties from Darzalex and Kesimpta.

The company’s financial strength prompted an upward revision of the full-year revenue guidance, suggesting increased confidence in solid performance by Genmab A/S (NASDAQ:GMAB), the analyst added.

Genmab A/S (NASDAQ:GMAB) is an international biotechnology company that develops human antibody therapeutics for the treatment of cancer and other diseases.

Its product pipeline includes DARZALEX to treat certain indications of multiple myeloma, TEPEZZA for the treatment of thyroid eye disease, and Arzerra to treat certain indications of chronic lymphocytic leukemia.

While we acknowledge the potential of GMAB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GMAB and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.